

ELTROXIN LIKE MIMIC ACTION OF *WITHANIA SOMNIFERA* LEAF EXTRACT IN HYPOTHYROID-INDUCED RATS

ABHILASHA PUROHIT*, ASHOK PUROHIT

Department of Zoology, Jai Narain Vyas University, Jodhpur, Rajasthan, India. Email: abhilashapurohit25@gmail.com

Received: 21 May 2018, Revised and Accepted: 11 July 2018

ABSTRACT

Objective: The present study was designed to examine the anti-hypothyroid activity of *Withania somnifera* (Ashwagandha)'s leaf extract on 6-n-propyl-2-thio-uracil (PTU) induced hypothyroid rats.

Method: Ethanolic extracts of *W. somnifera* leaf and Eltroxin were administrated to PTU induced hypothyroid rats. The animals were divided into control, PTU treatment, *W. somnifera* leaf extract treatment, and Eltroxin treatment groups for 60 days. The serum T₃ and T₄ were estimated, and biochemical and hematological parameters of the blood serum were also evaluated.

Results: PTU induction caused a significant decrease ($p \leq 0.001$) in T₃ and T₄ level when compared with the control group. Adverse effects of PTU were also observed in blood sugar, cholesterol, alkaline phosphate, protein, albumin, globulin, liver function test, and renal function test parameters. Non-significant changes in LFT, RFT and Other parameters were observed. *W. somnifera*'s leaf extract and Eltroxin treatment group recovered both of the thyroid hormone secretion as compare to control.

Keywords: 6-n-Propyl-2-thio-uracil, Hypothyroid, *Withania somnifera*, Eltroxin.

© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>) DOI: <http://dx.doi.org/10.22159/ajpcr.2018.v11i11.27424>

INTRODUCTION

Hypothyroidism is one of most the common endocrine disorder [1]. It is defined as a condition when the level of the thyroid hormones decreases below the normal need of the body [2]. The hypothyroidism is a complex hormonal dysfunction rather than a single hormonal defect [3]. Thyroid hormone is a powerful modulator of cardiac function [4]. Hypothyroidism causes the disturbance in body weight and appetite [5]. Even during pregnancy time, a significant change in thyroid hormone metabolism is observed [6]. Synthetic levothyroxine is recommended for hypothyroidism, actually, this drug elevates the T₃ and T₄ level in blood serum so that thyroid gland activity can be controlled [7]. Whereas, 6-n-propyl-2-thio-uracil (PTU) is prescribed for hyperthyroidism because it can decrease the amount of both thyroid hormones secreted by the thyroid gland [8]. Long duration usage of the synthetic drug can cure the hypothyroidism, but they cause side effects. L-thyroxin can damage the vital organs such as the liver and kidney, and it also causes the reduction in body weight and an increase in the relative body weight of the kidney [9]. Thus, there is a need to develop a drug from plants origin which can work for the hypothyroid treatment. Ayurveda suggests that some plant products cure hypothyroidism and some investigation on the effects of plant products on hypothyroidism is also found. Several bioactive compound has been derived from various plants, having anti-thyroidal activity and low toxicity as compare to synthetic drugs, e.g., :Bamboo shoot [10]. These plant products can control the basal metabolic rate of the body and several cardiovascular diseases like atherosclerosis [11]. These extracts have antioxidants and these can affect the metabolism of the body too [12]. *Withania somnifera* can effect on antioxidants of animal, and it can increase the serum T₃ and T₄ significantly. Its roots have a compound name withanolides which can cure many diseases [13,14]. Roots of the *W. somnifera* are used in Ayurveda to cure hypothyroidism. This study is designed to evaluate the effect of *W. somnifera* leaf extract on hypothyroidism. Therefore, we have performed an experiment to examine the effect of *W. somnifera* leaf extract on PTU induced hypothyroid rats. This study is aimed to finding

out whether *W. somnifera* leaves can increase Serum T₃, T₄ level and affect the thyroid gland activity positively.

METHODS

Extraction of plant material

W. somnifera plant's leaves were collected from Jodhpur, Rajasthan state, India, and scientific identification was done in the Department of Botany, Jai Narai Vyas University, Jodhpur. These leaves were extracted with 70% ethanol for 24–36 h by Soxhlet extraction method. Then, ethanol was separated under reduced pressure to obtain a blackish dark brown crude residue which was dissolved in distilled water and orally administrated to the animals.

Model animals

Wistar rats (150–250 g) were purchased from Certified Institute. Protocols for animal care, maintenance and experiments were followed given by Animal Ethical Committee (IAEC, Reg no.: 1646/GO/Re/12/CPCSEA). For this experiment, 20 female animals were housed in polypropylene cages containing corn-cob bedding and maintained at approximately 25–28° F on a 12-h light/dark cycle. For the animal adaptability, all rats had been fed for 1 week before the experiment. Rats were randomly divided into four groups.

Experimentation

Induction of hypothyroidism

Hypothyroidism was induced in euthyroid rats by administration of PTU at the dose of 10mg/kg in drinking water as well as orally for 30 days.

Dose regime of Eltroxin

Eltroxin was used as a standard drug to cure hypothyroid that was orally administrated at the dose of 0.5 µg/100 g body weight dissolved in 50 mL of distilled water.

Preparation of plant drug

The 70% ethanolic extract (500 mg/kg.b.wt.) was prepared then given to the experimentally induced hypothyroid rats.

Experimental design

The experimental period comprised 60 days and the rats were divided into the following groups (n=5).

- Group I: Intact control: Rats receiving normal slandered rat pallets with saline water.
- Group II: Hypothyroid control: Rats were orally injected PTU for hypothyroidism induction for 60 days.
- Group III: *W. somnifera* leaf extract's treatment group: PTU treated rats received *W. somnifera* leaf extracts (70% ethanolic extracts) for next 30 days on the dose of 500 mg/kg body weight.
- Group IV: Eltroxin treatment group: PTU treated rats received Eltroxin at the dose of 0.5 µg/100 g body weight for the next 30 days.

Serum biochemistry

At the end of the experiment, all rats were sacrificed under prolonged anesthesia and blood was collected through the direct cardiac puncture. Serum was separated and stored at -20°C until analyzed.

Assessment of hormone assays of T₃ and T₄

Total circulating T₃ and T₄ in serum were quantitatively determined by enzyme-linked immunosorbent assay following the protocols provided in the CALBIOTECH kits as routinely followed in our laboratory.

Assessment of liver function test (LFT), renal function test (RFT), and other parameters

For the RFT determination in blood serum urea, creatinine, and uric acid was estimated by the kit method. Whereas serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), bilirubin direct, bilirubin indirect, and bilirubin total were measured for the analysis of LFT. Other parameters such as blood sugar, cholesterol, alkaline phosphate, and protein were also evaluated by the kit method. All of these tests were analyzed using Biochem Analyzer RX-50 and commercial diagnostic kits (Siemens Healthcare Diagnostics, USA).

Statistical analysis

The mean and standard deviation was calculated in terms of mean ±SEM. One-way analysis of variance was used for parametric analysis of all groups and calculating the statistical differences between the means of the various groups.

Hematology

Blood was collected by direct cardiac puncture at the end of the experimental period. Collected blood was stored in EDTA vials at 20°C. Hematological assessments of hemoglobin, TRBC, HCT, MCV, MCH, MCHC, RDW, TLC, PLT, PCT, MPV, and PDW were examined through standard methods [15].

RESULTS

Hormone assay

Animals treated by PTU demonstrated significant reduction ($p \leq 0.001=c$) in serum level of T₃ and slightly significant reduction ($p \leq 0.05=a$) in T₄ level as compare to control groups whereas *W. somnifera* leaf extracts treated group's blood serum have demonstrated no significant changes in T₃ and T₄ level as compared to control groups. Moreover, when this Group III was compared to Group II, then it was observed that T₃ was significantly increase ($p \leq 0.001=g$) and T₄ had significant changes ($p \leq 0.01=f$). Eltroxin treatment demonstrated the highly significant changes in T₃ level as compared to the control group and no significant changes as compare to PTU group. Actually, *W. somnifera* and Eltroxin, both groups demonstrated the no significant changes in T₄ level as compare to control whereas significant changes ($p \leq 0.01=f$) were observed when compared to PTU treated rats. In both groups, T₄ exhibited significance ($p \leq 0.01=f$) (Figs. 1 and 2).

Morphological studies

Body weight and thyroid weight

No significant changes were observed in body weight in hypothyroid and all treatment groups. No significant changes were observed in relative body weight of liver, pancreas, and heart, although slight reduction in kidney weight was observed in the PTU treatment group as compared to control.

Relative body weight of pancreas, heart, kidney, and liver of Groups III and IV exhibited slightly differences, or no changes as compared to control and PTU treated groups. However, the statistically significant difference was observed in the thyroid weight between Group II (PTU treated Group) and Group I (control group). Whereas, slightly significance or significant changes in relative body weight of thyroid was observed in the next two groups (Groups III and IV) as compared to control and PTU treated groups (Table 1 and Fig. 3).

RFT

PTU causes some toxicity in kidney which can be observed in RFT parameters where significant, slightly significant, and highly significant changes were evaluated in urea, creatinine, and uric acid values as compared to control group. Whereas *W. somnifera* leaf extract treatment (Group III) and Eltroxin (Group IV) treatment groups had slightly or no significantly changes in these parameters as compared to control (Table 2).

LFT

LFT was also affected by PTU in which bilirubin total and bilirubin direct were slightly increased whereas SGOT, SGPT, and bilirubin direct were significantly increased as compared to the control group. However, *W. somnifera* leaf extract and Eltroxin treatment groups also exhibited some changes as compared to the control group (Table 3).

Other parameters

PTU causes some significant changes in blood, sugar, cholesterol, alkaline phosphate, albumin, and globulin parameters when compared to control group. There is significantly higher blood sugar and




Fig. 1: Effect of *Withania somnifera* (Ashwagandha) leaf extract on serum T₃ in compared to control, 6-n-propyl-2-thio-uracil and Eltroxin treatment groups




Fig. 2: Effect of *Withania somnifera* (Ashwagandha) leaf extract on serum T₄ in compare to control, 6-n-propyl-2-thio-uracil and Eltroxin treatment groups

Table 1: Comparative study of body weight and relative body weight of various organs in intact control, PTU treatment, *W. somnifera* leaf extract treatment and Eltroxin treatment groups

Group name	Body weight		Relative Body Weight				
	In g		mg/100 g body weight				
	Initial	Final	Thyroid	Pancreas	Heart	Kidney	Liver
Group I - intact control	123.33±13.33	115±1128	19.93±1.87	316.02±25.4	620.25±60	990±90.16	4.31±0.41
Group II - PTU treated	196.66±18.03	176.66±13.38	73.87±6.42 ^c	106.36±10.95 ^d	555±45.75 ^d	890±8.65 ^a	4.53±0.34 ^d
Group III - <i>W. somnifera</i> leaf treated	216.66±16.66	146.66±13.66	12.31±1.21 ^{b, g}	258.54±25.43 ^{a, g}	426.43±3.954 ^{a, e}	829.58±52.63 ^{b, f}	3.606±0.36 ^{d, e}
Group IV - Eltroxin treated	125±13	116±12.88	16.32±1.65 ^{a, g}	362.43±21.23 ^{d, g}	570.13±51.82 ^{d, h}	966.65±94.42 ^{d, e}	3.87±0.3 ^{d, e}

Values expressed as mean±SEM (n=5). Groups II-IV compared with Group I, where ^ap≤0.05, ^bp≤0.01, ^cp≤0.001, and ^dnon significant. Groups III and IV are compared with Group II, where ^ep≤0.05, ^fp≤0.01, ^gp≤0.001, and ^hnon significant. SEM: Standard error of the mean. PTU: 6-n-propyl-2-thio-uracil, *W. somnifera*: *Withania somnifera*

Table 2: Comparative analysis of various parameters of RFT in all groups

Group name	Urea (mg/dL)	Creatinine (mg/dL)	Uric acid (mg/dL)
Group I (control)	36.33±3.63	0.96±0.08	4.16±0.48
Group II (PTU treatment)	47.36±3.27 ^b	1.06±0.1 ^a	15.36±1.38 ^c
Group III (<i>W. somnifera</i> leaf extracts treatment)	35.66±3.61 ^{d, h}	0.8±0.08 ^{d, h}	4.63±0.3 ^{d, h}
Group IV (Eltroxin treatment)	36.56±3.56 ^{d, h}	0.92±0.06 ^{a, h}	3.35±0.46 ^{d, h}

Values expressed as mean±SEM (n=5). Groups II-IV compared with Group I, where ^ap≤0.05, ^bp≤0.01, ^cp≤0.001, and ^dnon significant. Groups III and IV are compared with Group II, where ^ep≤0.05, ^fp≤0.01, ^gp≤0.001, and ^hnon significant. SEM: Standard error of the mean. *W. somnifera*: *Withania somnifera*, RFT: Renal function test

Table 3: Comparative study of various parameters of LFT in all groups

Group name	Bilirubin total (mg/dL)	Bilirubin direct (mg/dL)	Bilirubin indirect (U/L)	SGOT (U/L)	SGPT (U/L)
Group I (control)	0.49±0.037	0.13±0.012	0.32±0.02	37.66±3.26	35.1±3.58
Group II (PTU treatment)	0.70±0.05 ^b	0.20±0.018 ^b	0.27±0.025 ^c	148.3±10.15 ^c	312.3±29.18 ^c
Group III (<i>W. somnifera</i> leaf extract treatment)	0.86±0.077 ^{c, h}	0.51±0.027 ^{c, g}	0.29±0.021 ^{c, h}	53.7±5.35 ^{a, g}	41.05±4.66 ^{d, g}
Group IV - (Eltroxin treatment)	0.59±0.049 ^{a, h}	0.12±0.011 ^{d, f}	0.37±0.024 ^{c, f}	134.55±11.88 ^{c, e}	73.85±5.86 ^{c, g}

Values expressed as mean±SEM (n=5). Groups II-IV compared with Group I, where ^ap≤0.05, ^bp≤0.01, ^cp≤0.001 and ^dnon significant. Groups III and IV are compared with Group II, where ^ep≤0.05, ^fp≤0.01, ^gp≤0.001 and ^hnon significant. SEM: Standard error of the mean. SGPT: Serum glutamic pyruvic transaminase, LFT: Liver function test, SGOT: Serum glutamic oxaloacetic transaminase, *W. somnifera*: *Withania somnifera*

Table 4: Comparative study of other parameters in blood serum of the rats in all groups

Group name	Blood sugar (mg/dL)	Cholesterol (mg/dL)	Alkaline phosphate (U/L)	Protein (g/dL)	Albumin (mg/dL)	Globulin (mg/dL)
Group I (control)	79±5.77	75.7±6.7	250.73±25.28	6.73±0.46	2.8±0.2	3.9±0.34
Group II (PTU treated)	121.26±11.283 ^b	151±3.46 ^c	121.75±13.7 ^c	5.38±0.43 ^d	2.19±0.21 ^a	2.17±0.15 ^c
Group III - <i>W. somnifera</i> leaf extract treatment	84.03±7.96 ^{d, e}	75.76±4.06 ^{d, g}	182.91±18.06 ^{b, e}	5.83±0.44 ^{d, h}	3.8±0.36 ^{a, f}	3.56±0.24 ^{d, g}
Group IV - (Eltroxin treatment)	91.12±8.24 ^{d, h}	72.86±4.42 ^{d, e}	349.6±12.41 ^{b, g}	7.36±0.58 ^{d, h}	3.08±0.36 ^{d, e}	4.2±0.34 ^{d, g}

Values expressed as mean±SEM (n=5). Group II-IV compared with Group I, where ^ap≤0.05, ^bp≤0.01, ^cp≤0.001 and ^dnon significant. Groups III and IV are compared with Group II, where ^ep≤0.05, ^fp≤0.01, ^gp≤0.001, and ^hnon significant. SEM: Standard error of the mean, *W. somnifera*: *Withania somnifera*

cholesterol level observed in blood serum of PTU treated the group as compare to control whereas Groups III and IV exhibited no changes or slightly changes as compared to control in blood sugar and serum cholesterol. There were no significant changes observed in protein during experimentation (Table 4).

Hematology profile

All parameter of hematology was calculated when compared with control (Table 5).

DISCUSSION

The thyroid gland is a small but most important gland in the mammalian body; it plays a pivotal role in overall body function and homeostasis.

Thyroid gland secret 93% of the thyroxine (T_4) which is a metabolically inactive hormone and 7% tri-iodothyronine (T_3) although later on almost all thyroxine is converted in tri-iodothyronine [16]. Thyroid hormone exerts a broad range of effects on growth, metabolism, and development. The medical manifestations of thyroid hormone excess or deficiency are remarkable examples of the innumerable actions of the hormone. The primary secretions of the thyroid are thyroxine (T_4) which are relatively inactive and are converted to the active hormone, tri-iodothyronine (T_3), by the enzyme thyroxine 5'-deiodinase [17]. In the present study, PTU was used to induce hypothyroidism in rats. PTU blocks the oxidative iodination in the thyroid gland so that thyroid hormone-like thyroxine (T_4) and tri-iodothyronine (T_3) level decrease in serum [18], in the present investigation, we have reported similar findings. Synthetic drug Eltroxin which is commonly used at

Table 5: Comparison of various hematological parameters in all groups

Group name	Group I (control)	Group II (PTU treatment)	Group III (<i>W. somnifera</i> leaf extract treatment)	Group IV (Eltroxin treatment)
Hemoglobin (g%)	12.6±0.63	13.5±1.26	11.46±0.5	13.13±0.7
TRBC (mil/mm ³)	7.08±0.51	4.25±0.33	4.26±0.32	6.18±0.52
HCT (%)	37.06±2.32	23.6±2.23	38.46±1.89	23.6±2.2
MCV (fL)	52.53±5.29	54±5.98	88.63±6	54.56±4.63
MCH (pg)	17.76±1.18	18.6±1.05	23.93±0.8	17.7±1.18
MCHC (g/dL)	33.8±3.04	36.46±3.58	26.6±1.96	33.63±1.02
RDW (%)	16.16±1.16	16.16±1.16	13.66±0.63	14.8±0.78
TLC (th/mm ³)	10,053±611.91	7883.33±692.69	5633.33±837.32	6883.33±697.53
Neutrophil	10.66±1.76	16.66±1.84	38.66±3.45	8.63
Lymphocyte	76±2.43	65±4.72	66±5.5	8±0.5
Monocyte	6.9±0.39	10.66±1.16	4.56±0.34	11.33±1.17
Eosinophil	4.6±0.305	3.3±0.38	8±0.5	5±0.53
PLT	4.35±0.32	2.31±0.28	3.1±0.32	3.51±0.30
	lacs/cummm	lac/cumm	lac/cumm	lac/cumm
PCT	0.27±0.02	0.16±0.015	0.24±0.02	0.22±0.02
MPV	6.8±0.65	7.73±0.58	6.7±0.58	6.43±0.48
PDW	9.5±0.5	9.76±0.55	8.13±0.84	7.5±0.6

PLT: Platelet count, MPV: Mean platelet volume, *W. somnifera*: *Withania somnifera*




Fig. 3: Thyroid weight of rats in various experimental groups. Values expressed as mean±SEM (n=5). Groups II-IV compared with Group I, where^ap≤0.05,^bp≤0.01,^cp≤0.001, and^dnon significant. Groups III and IV are compared with Group II, where^ep≤0.05,^fp≤0.01,^gp≤0.001, and^hnon significant. SEM -Standard error of the mean

the different dosage to control hypothyroidism in human being shows a significant increase of T_4 and T_3 level. In the present investigation, Eltroxin was used as a standard drug which causes significant improvement in T_3 and T_4 level in hypothyroid rats. Similar findings have been reported by plant-like *W. somnifera* and *Bauhinia purpurea* in female mice [19]. This is mainly due to changing the inactive hormone to active hormone [20,21]. The green medicine (*W. somnifera*'s leaf extract) can also increase the level of T_3 and T_4 in the experimental group without any side effects. This is mainly due to beneficial effects of plant extract on the thyroid gland. The improvement of T_3 and T_4 suggests that plant extract possesses T_3 and T_4 like compound, which mimics like Eltroxin [22,23]. Some plants show thyroid stimulating actions [24] and suggested that green medicines positively effect on serum T_3 and T_4 . Besides this, they increase the hepatic glucose-phosphate activity and hepatic-lipid-peroxidase activity [25]. In the present investigation, increase of glucose was reported in blood and abnormal function of kidney and liver by PTU treatment. This is mainly due to the adverse effect of PTU on the vital organs. In the present investigation when the plant extract was given to PTU induced hypothyroid rats, all these parameters come to the normal range which shows a beneficial effect of *W. somnifera* leaf extract in controlling hypothyroid without showing any toxicity on liver and kidney. These findings reported by a different scientist on plant product which shows low toxicity of green medicine [26]. The current study indicates that the plant extracts are having no toxicity which is reflecting in hematology. All parameters of hematology in treatment groups were within the normal range. The current study

recommends that *W. somnifera* extract can cure hypothyroidism without causing any adversity on the vital organ as well as on hematology.

CONCLUSION

The present finding reveals that *W. somnifera* leaf extract can control the hypothyroidism. It normalize the T_3 and T_4 level in blood serum. Moreover, it does not show any toxicity in any of the LFT and RFT parameters and hematology of the rat's blood.

ACKNOWLEDGMENT

We would like to acknowledge Head of the Department of Zoology, Jai Narain Vyas University, Jodhpur (Rajasthan), for providing all necessary amenities.

AUTHOR CONTRIBUTION

The complete research work was suggested and designed by Ashok Purohit. All experiments were carried out by Abhilasha Purohit. Authors drafted and approved the final manuscript.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interests.

REFERENCES

- Mahmoud GS, Abd EL-Aziz AE, Muhammed AA. The protective effect of *Garcinia* on cardiovascular system of propylthiouracil induced hypothyroid rat. IOSR J Dent Med Sci 2016;15:103-12.
- Korac A, Milosevic MC, Davidovic V. Methimazole-induced hypothyroidism in rats: Effects on body weight and histological characteristics of thyroid gland. Jugoslav Med Biochem 2004;23:143-7.
- Oncu M, Kanter M, Gokcimen A, Kavakli D, Oncu M, Ural M. Effect of thyroidectomy on the histology of rat sublingual gland. APMIS 2004;112:119-22.
- Bacova BS, Viczenczova C, Benova TE, Soukup T, Rauchova H, Pavelka S, et al. Cardiac connexin-43 and PKC signaling in rats with altered thyroid status without and with omega-3 fatty acids intake. Physiol Res 2016;65:S77-90.
- Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid 1995;5:481-92.
- Hebbar S, Kumar S, Amin S, Doizode S. Subclinical hypothyroidism in pregnancy; Is there a need for pharmacological intervention? Int J Pharm Pharm Sci 2017;9:186-191.
- Ezz MK, Hassan RE, Esmat AY. Pineapple juice supplementation activates thyroid gland and attenuates hyperlipidemia in rats. Int J Biosci 2017;10:173-84.
- Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N.

- Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. *J Clin Endocrinol Metab* 2007;92:2157-62.
9. Sinha S, Chakraborty A, Mondal C, Chandra AK. Effect of Vitamin acetate supplementation on thyroid hormone-sensitive organs following exogenous L-thyroxine treatment. *Asian J Pharm Clin Res* 2018;11:123-9.
 10. Sarkar D, Chakraborty A, Bhattacharya C, Singh LH, Chandra AK. Exploration of Goitrogenic/antithyroidal potentiality of bamboo-shoots in relation to Thiourea. *Int J Pharm Pharm Sci* 2017;9:7-12.
 11. Panda S, Kar A. Guggulu (*Compiphora mukul*) potentially ameliorates hypothyroidism in female mice. *Phytother Res* 2005;19:78-80.
 12. Purohit A, Vyas KB. Hypolipidaemic efficacy of *Capparis decidua* fruit and shoot extract in cholesterol fed rabbits. *Indian J Exp Biol* 2005;43:863-6.
 13. Tripathi P, Singh A. Natural resources from plants in the treatment of cancer: An update. *Asian J Pharm Clin Res* 2017;10:172-81.
 14. Verma SK, Kumar A. Therapeutic uses of *Withania somnifera* (Ashwagandha) with a note on withanolids and its pharmacological actions. *Asian J Pharm Clin Res* 2011;4:1-4.
 15. Wintrobe WM. In: Greer JP, Wintrobe MM, editors. *Wintrobe's Clinical Hematology*. 12th ed. USA: Lippincott Williams & Wilkins Health; 2011. p. 121-225.
 16. Alkalby JM, Alzerjawi SJ. Effect of propylthiouracil-induced hypothyroidism on reproductive efficiency of adult rats. *Bas J Vet Res* 2013;12:113-21.
 17. Breant GA. The molecular basis of thyroid hormone action. *N Engl J Med* 1994;331:847-53.
 18. Geffner LD, Azukizawa M, Hershman JM. Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine. *J Clin Invest* 1975;55:224-9.
 19. Panda S, Kar A. *Withania somnifera* and *Bauhinia purpurea* in the regulation of circulating thyroid hormone concentrations in female mice. *J Ethnopharmacol* 1999;67:233-9.
 20. Griffen EE, Miller LL. Effects of hypothyroidism, hyperthyroidism, and thyroxine on net synthesis of plasma proteins by the isolated perfused rat liver. *J Biol Chem* 1972;248:4716-23.
 21. Bindu N, Kenneth B. Thyrotoxicosis and thyroid stor. *Endocrinol Metab Clin North Am* 2006;35:663-86.
 22. Chadha R, Purohit A. Wheat bran extract mimics statin like action in hyperlipidemic rabbits: An experimental study. *Asian J Pharm Clin Res* 2018;11:402-5.
 23. Jatwa R, Kar A. Amelioration of metformin-induced hypothyroidism by *Withania somnifera* and *Bauhinia purpurea* extracts in Type 2 diabetic mice. *Phytother Res* 2009;23:1140-5.
 24. Kar A, Panda S. Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentration in male mice. *J Ethnopharmacol* 2002;81:281-5.
 25. Panda S, Kar A. Changes in thyroid hormone concentrations after administration of Ashwagandha root extract to adult male mice. *J Pharm Pharmacol* 1998;50:1065-8.
 26. Panda S, Kar A. *Withania somnifera* and *Bauhinia purpurea* in the regulation of circulating thyroid hormone concentration in female mice. *J Ethnopharmacol* 1999a;67:233-9.